PATENT CLAIM ANALYSIS

Application Number: 16203654
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-05
Patent Classification: ["424", "093210"]

Abstract:
Disclosed herein is a method for manufacturing a population of human insulin producing cells from non-pancreatic β-cells, wherein the resulting insulin producing cells have increased insulin content, or increased glucose regulated secretion of insulin, or a combination of both.

Claim (Index 1):
A method of large-scale production of human insulin producing cells, the method comprising the steps of:\n (a) seeding a multilayer cell culture flask with a seeding dose of primary human adult liver cells; (b) propagating and expanding the cells to a predetermined number of cells, wherein said predetermined number of cells comprises at least about 1\u00d710 9  cells, and said propagating and expanding comprises use of at least a first and a second bioreactor; (c) transdifferentiating the expanded cells, wherein the transdifferentiating comprises:\n (1) infecting the expanded cells with at least one expression vector at a first time period,\n (i) wherein the at least one expression vector comprises an adenoviral vector comprising a nucleic acid encoding a PDX-1 polypeptide and an expression vector comprising an adenoviral vector comprising a nucleic acid encoding a second pancreatic transcription factor polypeptide selected from NeuroD1 and Pax4, wherein the infecting with said adenoviral vectors occurs at the same time, or \n (ii) wherein the at least one expression vector comprises an adenoviral vector comprising a nucleic acid encoding a PDX-1 polypeptide and a second pancreatic transcription factor polypeptide selected from NeuroD1 and Pax4; and \n \n (2) infecting the expanded cells of (1) with an adenoviral vector comprising a nucleic acid encoding a MafA polypeptide, the infecting occurring at a second time period, wherein the second time period is after the first time period; and \n (d) harvesting said transdifferentiated cells from the at least second bioreactor, wherein the number of transdifferentiated cells harvested comprises the predetermined number of cells decreased by less than 20% during harvesting; thereby producing a large-scale production of human insulin producing cells, said cells having an increased insulin content, or increased glucose regulated insulin secretion, or increased regulated C-peptide secretion, or any combination thereof, compared with control non-transdifferentiated human primary adult liver cells.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.43333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14983657', '14897262', '14330965', '10843801', '10113118']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7212662001366332
- 35 USC 102 Novelty (BERT): 0.6913872162346879
- Combined Prediction Score: 0.7182783017464387
- Mean Citation Score: 516.661872
- Max Citation Score: 831.7019700000003
- Similarity Product: 671.1165999407818

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test